Affordable Access

deepdyve-link
Publisher Website

Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology.

Authors
  • Pineles, Stacy L1
  • Kraker, Raymond T2
  • VanderVeen, Deborah K3
  • Hutchinson, Amy K4
  • Galvin, Jennifer A5
  • Wilson, Lorri B6
  • Lambert, Scott R7
  • 1 Jules Stein Eye Institute, Los Angeles, California.
  • 2 Jaeb Center for Health Research, Tampa, Florida.
  • 3 Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • 4 Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. , (Georgia)
  • 5 Eye Surgery Associates, LLC, Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut.
  • 6 Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
  • 7 Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California.
Type
Published Article
Journal
Ophthalmology
Publication Date
Dec 01, 2017
Volume
124
Issue
12
Pages
1857–1866
Identifiers
DOI: 10.1016/j.ophtha.2017.05.032
PMID: 28669492
Source
Medline
License
Unknown

Abstract

Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).

Report this publication

Statistics

Seen <100 times